TF
Tom Frohlich
Chief Executive Officer

Tom Frohlich insider trades: Jade Biosciences (JBIO) stock buys and sales

Chief Executive Officer, Jade Biosciences Last trade May 16, 2025 18 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2021
2
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Tom reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 16, 2025JBIO↑ Buy$44K
Feb 10, 2023KDNY↓ Sell$88K
Jan 31, 2023KDNY↓ Sell$113K
Dec 13, 2022KDNY↓ Sell$250K
Nov 7, 2022KDNY↓ Sell$222K
Oct 6, 2022KDNY↓ Sell$145K
Feb 11, 2022KDNY↓ Sell$48K
Nov 10, 2021KDNY↓ Sell$96K
Nov 8, 2021KDNY↓ Sell$489K
Sep 24, 2021KDNY↓ Sell$260K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Tom Frohlich's insider trades

Tom Frohlich is Chief Executive Officer at Jade Biosciences (JBIO). Since Sep 24, 2021, Tom has reported 1 open-market purchase worth $44K and 9 sales worth $1.7M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include option exercises (9 filings), grants and awards (6 filings), shares returned to the company (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.